slL6xR Specific Neutra™ Antibody Products

Struggling with prolonged therapeutic development or inconsistent antibody performance? Creative Biolabs' slL6xR-specific neutra™ antibody products leverage advanced recombinant engineering and high-throughput validation to accelerate your immunotherapeutic breakthroughs.

Introduction to slL6xR

The soluble IL6/IL6R (slL6xR) complex is a heterodimeric signaling molecule central to inflammation, immune regulation, and cancer progression. Composed of interleukin-6 (IL6) and its soluble receptor (sIL6R), this complex activates downstream pathways via glycoprotein 130 (gp130) even in cells lacking membrane-bound IL6R, a mechanism termed trans-signaling. Elevated slL6xR levels correlate with chronic inflammatory diseases and malignancies, making it a high-priority therapeutic target.

• Structural Insights into slL6xR

The slL6xR complex forms a hexameric structure: two IL6 molecules, two sIL6R chains, and two gp130 subunits. IL6 binds sIL6R through high-affinity interactions at its site I and II domains, while sIL6R recruits gp130 via site III. This assembly initiates signal transduction. Structural studies reveal that the IL6-sIL6R-gp130 ternary complex stabilizes through hydrophobic interactions and hydrogen bonding, enabling prolonged activation of downstream effectors. Targeting these interfaces with neutralizing antibodies disrupts complex assembly, effectively blocking pathological signaling.

• Key Signaling Pathways

slL6xR activates the JAK/STAT3, MAPK, and PI3K/Akt pathways. Persistent JAK/STAT3 signaling drives pro-inflammatory cytokine production, tumor cell proliferation, and immune evasion. MAPK and PI3K/Akt cascades further promote cell survival and angiogenesis. Dysregulation of these pathways underlies autoimmune disorders (e.g., rheumatoid arthritis), cancers (e.g., multiple myeloma), and inflammatory conditions (e.g., Crohn's disease).

Fig. 1 IL-6R structure and signaling.¹

• Disease Associations

The slL6xR complex is implicated in pathologies characterized by chronic inflammation and uncontrolled cell growth. In rheumatoid arthritis, slL6xR-mediated trans-signaling perpetuates synovial inflammation and joint destruction. In oncology, elevated slL6xR levels correlate with poor prognosis in lymphoma and solid tumors due to STAT3-driven metastasis and therapy resistance. Neutralizing this complex offers a dual therapeutic strategy: suppressing inflammation and inhibiting tumor progression.

Applications of slL6xR Neutralizing Antibodies

• Therapeutic Development: Targeting Chronic Inflammation and Cancer

slL6xR-neutralizing antibodies suppress trans-signaling in autoimmune and oncologic models. Preclinical studies demonstrate reduced cytokine storm severity and tumor burden, supporting their use in combination therapies.

• Diagnostic Assays: Quantifying Pathological Signaling

These antibodies enable precise quantification of slL6xR in serum or tissue samples via ELISA or multiplex platforms, aiding biomarker discovery and patient stratification.

• Mechanistic Studies: Unraveling Signaling Dynamics

In research settings, slL6xR antibodies elucidate pathway crosstalk, receptor trafficking, and therapeutic resistance mechanisms. For example, co-immunoprecipitation studies using these antibodies have identified novel slL6xR interactors in tumor microenvironments.

• Preclinical Validation: Accelerating Candidate Selection

Creative Biolabs' antibodies are compatible with in vivo models to assess efficacy and safety, streamlining translational research.

Antibodies Targeting slL6xR

Creative Biolabs' slL6xR-specific neutralizing antibodies are engineered to block IL6-sIL6R binding or disrupt gp130 recruitment. Applications span mechanistic studies, drug screening, and companion diagnostics. These antibodies demonstrate exceptional specificity, validated through surface plasmon resonance (SPR) and cell-based assays. Key features include:

-High affinity (K_D <1 nM): Ensures effective complex neutralization at low concentrations.

-Cross-species reactivity: Supports preclinical testing in murine and primate models.

-Functional validation: Confirmed inhibition of STAT3 phosphorylation in IL6-dependent cell lines.

Creative Biolabs delivers rigorously validated slL6xR-specific antibodies to accelerate your therapeutic and diagnostic programs. Our products are backed by ISO-certified manufacturing and dedicated technical support. Contact our scientific team to discuss your project requirements.

REFERENCE

1. Druszczyńska, Magdalena, et al. "Cytokine receptors—regulators of antimycobacterial immune response." International Journal of Molecular Sciences 23.3 (2022): 1112. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms23031112